SCHEMBL2305298

SCHEMBL2305298

O=[C]CC1SC(=O)NC1=O

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 3/20 0.53
▸ KDM4E B2RXH2 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ MAPT P10636 4/20 0.44
▸ MAOA P21397 2/20 0.44
▸ CISD1 Q9NZ45 2/20 0.44
▸ MAOB P27338 1/20 0.42
▸ PPARG P37231 4/20 0.39
▸ ALDH1A1 P00352 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ CA2 P00918 2/20 0.36
▸ FFAR1 O14842 1/20 0.36
▸ PPARA Q07869 1/20 0.36
▸ ESR2 Q92731 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ PTPN1 P18031 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5820358 0.79 MAOB (0.50) TSHRKDM4EHTTMAOB
SCHEMBL8840901 0.77 TSHR (0.61) TSHRKDM4EHTTMAPTMAOA
SCHEMBL8811471 0.74 TSHR (0.48) TSHRKDM4EHTTMAPTMAOA
SCHEMBL264929 0.73 — —
SCHEMBL15427287 0.73 — —
SCHEMBL4859366 0.73 — —
SCHEMBL4859372 0.73 — —
SCHEMBL1363461 0.73 — —
SCHEMBL16924077 0.73 — —
SCHEMBL5814733 0.71 HSD17B10 (0.61) TSHRKDM4EHTTMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2350311-B1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS MADRIGAL PHARMACEUTICALS INC (US) 2013-12-25 — — EP claimed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 — — US claimed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 — — EP claimed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 — — WO claimed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 — — US claimed
US-8324385-B2 Diacylglycerol acyltransferase inhibitors MADRIGAL PHARMACEUTICALS, INC. (US) 2012-12-04 — — US disclosed
EP-2350311-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS Via Pharmaceuticals, Inc. (US) 2011-08-03 — — EP disclosed
WO-2010056506-A1 DIACYLGLYCEROL ACLYTRANSFERASE INHIBITORS VIA PHARMACEUTICALS, INC. (US) 2010-05-20 — — WO disclosed
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors MADRIGAL PHARMACEUTICALS, INC. 2010-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113782-A1 Diacylglycerol Acyltransferase Inhibitors DGAT2, DGAT1, MOGAT2 TSHR 1010/4885KDM4E 3683/4885HTT 2451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback